Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Mitomycin C

N W Gibson1, D Ross

  • 1Cancer Research Group, Central Research Pfizer Inc., Groton, CT.

Cancer Chemotherapy and Biological Response Modifiers
|January 1, 1993
PubMed
Summary
This summary is machine-generated.

Non-small cell lung cancers (NSCLCs) show increased NQO1 activity, making it a promising therapeutic target. Developing NQO1-activated drugs is crucial for improving lung cancer survival rates.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Case ascertainment of heat illness in the British Army: evidence of under-reporting from analysis of Medical and Command notifications, 2009-2013.

Journal of the Royal Army Medical Corps·2015
Same author

Extended lateral pelvic sidewall excision (ELSiE): an approach to optimize complete resection rates in locally advanced or recurrent anorectal cancer involving the pelvic sidewall.

Techniques in coloproctology·2015
Same author

Extended lateral pelvic sidewall excision (ELSiE): an approach to optimize complete resection rates in locally advanced or recurrent anorectal cancer involving the pelvic sidewall.

Techniques in coloproctology·2014
Same author

Screening for latent tuberculosis and gastrointestinal parasite infections in Gurkha recruits: research driving policy change.

Journal of the Royal Army Medical Corps·2014
Same author

Heat illness in military populations: asking the right questions for research.

Journal of the Royal Army Medical Corps·2014
Same author

High uptake of HPV immunisation in Scotland--perspectives on maximising uptake.

Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin·2013
Same journal

Native and genetically engineered anti-disialoganglioside monoclonal antibody treatment of melanoma.

Cancer chemotherapy and biological response modifiers·2005
Same journal

Human tumor associated antigen mimicry by xenoantigens, anti-idiotypic antibodies and peptide mimics: implications for immunotherapy of malignant diseases.

Cancer chemotherapy and biological response modifiers·2005
Same journal

DNA vaccines for melanoma.

Cancer chemotherapy and biological response modifiers·2005
Same journal

Immunizing against partially defined antigen mixtures, gangliosides, or peptides to induce antibody, T cell, and clinical responses.

Cancer chemotherapy and biological response modifiers·2005
Same journal

Chemotherapy, cytokines, and biochemotherapy for melanoma.

Cancer chemotherapy and biological response modifiers·2005
Same journal

Current status of interferon-alpha in the treatment of melanoma.

Cancer chemotherapy and biological response modifiers·2005
See all related articles

Area of Science:

  • Oncology
  • Biochemistry

Background:

  • Non-small cell lung cancer (NSCLC) has a dismal 5-year survival rate.
  • Lung cancer accounts for a high number of annual cancer deaths worldwide.
  • Elevated levels of NAD(P)H:quinone oxidoreductase 1 (NQO1) activity are observed in NSCLCs.

Purpose of the Study:

  • To highlight NQO1 activity as a therapeutic target in NSCLC.
  • To emphasize the urgent need for novel therapeutic strategies against lung cancer.

Main Methods:

  • Analysis of NQO1 activity levels in NSCLC tissues.
  • Review of existing and potential therapeutic molecules activated by NQO1.

Main Results:

  • NSCLCs exhibit significantly elevated NQO1 activity compared to normal lung tissue.

Related Experiment Videos

  • NQO1 activity represents a viable target for selective cancer therapy.

    • Conclusions:

    • Targeting NQO1 in NSCLC offers a promising therapeutic avenue.
    • Development of NQO1-activated prodrugs (e.g., MeDZQ, CB 10-200) is a critical area for research.
    • Exploiting NQO1 activity could lead to improved treatment outcomes for lung cancer patients.